Format

Send to

Choose Destination
Drug Discov Today. 2016 Mar;21(3):454-64. doi: 10.1016/j.drudis.2016.01.016. Epub 2016 Feb 6.

Emerging treatment mechanisms for depression: focus on glutamate and synaptic plasticity.

Author information

1
Department of Psychology, Yale University, New Haven, CT 06511, United States.
2
Molecular Psychiatry, Yale University, New Haven, CT 06711, United States.
3
Molecular Psychiatry, Yale University, New Haven, CT 06711, United States. Electronic address: ronald.duman@yale.edu.

Abstract

Major depression is a chronic and debilitating illness that effects approximately 1 in 5 people, but currently available treatments are limited by low rates of efficacy, therapeutic time lag, and undesirable side effects. Recent efforts have been directed towards investigating rapid-acting agents that reverse the behavioral and neuronal deficits of chronic stress and depression, notably the glutamate NMDA receptor antagonist ketamine. The cellular mechanisms underlying the rapid antidepressant actions of ketamine and related agents are discussed, as well as novel, selective glutamatergic receptor targets that are safer and have fewer side effects.

PMID:
26854424
PMCID:
PMC4803609
[Available on 2017-03-01]
DOI:
10.1016/j.drudis.2016.01.016
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center